⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

December 15, 2015Clinical EndocrinologyOpen Access

TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas

Martyn Bullock Yan Ren Christine J. O’Neill Anthony J. Gill Adam Aniss Mark Sywak Stan B. Sidhu Leigh Delbridge Diana Learoyd Florent de Vathaire Bruce G. Robinson Roderick Clifton‐Bligh

View Full Paper

Ask AI

Bookmark

Share

Abstract

TERT promoter mutations are a major indicator of death due to PTCs. Conversely, absence of TERT mutations portends better survival.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bullock et al. (2015) studied this question.

synapsesocial.com/papers/69dcc7d6a5c75be4cfe5435e https://doi.org/10.1111/cen.12999

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Specific Association of Human Telomerase Activity with Immortal Cells and CancerOriginal Research · 1994 · 7,091 citations
2<i>TERT</i> Promoter Mutations in Familial and Sporadic MelanomaOriginal Research · 2013 · 1,802 citations
3Highly Recurrent <i>TERT</i> Promoter Mutations in Human MelanomaOriginal Research · 2013 · 1,815 citations
4Frequency of TERT promoter mutations in human cancersOriginal Research · 2013 · 901 citations
5Highly prevalent TERT promoter mutations in aggressive thyroid cancersOriginal Research · 2013 · 613 citations

More related papers

Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease2013
<i>TERT</i>Promoter Mutations and Their Association with<i>BRAF</i>V600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer2014
<i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence2014

More from Clinical Endocrinology

Endoscopic Ultrasound‐Guided Ethanol Ablation for Benign Insulinoma: A Single‐Centre Experience and Literature ReviewWed,
LGALS3 Drives Dopamine Agonist Resistance in Prolactinoma by Activating the MAPK/ERK Pathway: A Multi‐Omics StudyWed,